(Q53558680)

15 May 2018

review article

1 reference

title

Placebo-controlled studies in rheumatoid arthritis: ethical issues. (English)

1 reference

15 May 2018

1 reference

1 reference

C M Stein

1

1 reference

15 May 2018

T Pincus

series ordinal

2

1 reference

15 May 2018

language of work or name

English

0 references

publication date

1 January 1999

1 reference

15 May 2018

published in

The Lancet

1 reference

15 May 2018

volume

353

1 reference

15 May 2018

issue

9150

1 reference

15 May 2018

page(s)

400-403

1 reference

15 May 2018

The Randomized Clinical Trial

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901373-7

7 January 2021

An additional basic science for clinical medicine: II. The limitations of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901373-7

7 January 2021

Disclosure to the reader of institutional review board approval and informed consent.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901373-7

7 January 2021

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901373-7

7 January 2021

Scientific and ethical issues in the use of placebo controls in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901373-7

7 January 2021

The continuing unethical use of placebo controls

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901373-7

7 January 2021

The ethics of placebo treatment in rheumatoid arthritis drug trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901373-7

7 January 2021

Does Drug Therapy Slow Radiographic Deterioration in Rheumatoid Arthritis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901373-7

7 January 2021

Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901373-7

7 January 2021

The Roche Rheumatology Prize Lecture. The optimal management of early rheumatoid disease: the key to preventing disability

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901373-7

7 January 2021

The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis results of two metaanalyses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901373-7

7 January 2021

Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901373-7

7 January 2021

Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901373-7

7 January 2021

Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901373-7

7 January 2021

Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901373-7

7 January 2021

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901373-7

7 January 2021

The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901373-7

7 January 2021

Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin a

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901373-7

7 January 2021

Progression of functional disability in patients with rheumatoid arthritis. Associations with rheumatology subspecialty care

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901373-7

7 January 2021

The relative toxicity of disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901373-7

7 January 2021

Informed consent: study of quality of information given to participants in a clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901373-7

7 January 2021

10.1016/S0140-6736(98)01373-7

Identifiers

DOI

1 reference

15 May 2018

release_dbmz5kgm6rgvdbojoe47yen32m

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dbmz5kgm6rgvdbojoe47yen32m

24 November 2022

mapped directly with Wikidata item

1 reference

15 May 2018